Expanding access to a choice-based multi-method PrEP market for HIV prevention.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Trends in HIV Incidence, Prevalence, Antiretroviral Therapy Coverage and Mother-to-Child Transmission Among Pregnant and Breastfeeding Women in the Eastern Cape Province, South Africa, 2000-2023.Tropical medicine and infectious disease · 2026
   Article
2. Willingness to pay for injectable HIV pre-exposure prophylaxis among male and female sex workers in Uganda.Archives of public health = Archives belges de sante publique · 2026
   Article
3. PrEP and choice counselling - Insights into implementation.Journal of public health in Africa · 2026
   Article
4. Preferences for long-acting injectable HIV pre-exposure prophylaxis service delivery among male and female sex workers in Uganda: A discrete choice experiment.PLOS global public health · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.